Kodiak Sciences recently revealed that its Phase III GLOW study of tarcocimab tedromer, a 5 mg ABC therapy for moderate to severe NPDR, met its primary one-year endpoint.

This article summarized the latest R&D progress of Pegvisomant, the Mechanism of Action for Pegvisomant, and the drug target R&D trends for Pegvisomant.

4-1BB (also known as CD137 or TNFRSF9) was first discovered in 1989 and is a critical co-stimulation receptor on T cells and other immune cells.

This article summarized the latest R&D progress of Penicillin G Procaine, the Mechanism of Action for Penicillin G Procaine, and the drug target R&D trends for Penicillin G Procaine.

Abbisko Therapeutics recently reported that its self-developed small molecule FGFR4 inhibitor ABSK012, aimed at drug-resistant mutations, has received FDA approval to begin phase I human trials with advanced solid tumor patients.

This article summarized the latest R&D progress of Pentobarbital Sodium, the Mechanism of Action for Pentobarbital Sodium, and the drug target R&D trends for Pentobarbital Sodium.

The TLR agonists used in vaccine formulations come in various forms, ranging from lipopeptides to single-stranded DNA and RNA.

This article summarized the latest R&D progress of Nepafenac, the Mechanism of Action for Nepafenac, and the drug target R&D trends for Nepafenac.

MoonLake Immunotherapeutics recently announced positive results from the global Phase 2 clinical trial, ARGO, assessing the efficacy and safety of its nanobody, sonelokimab, in patients with active psoriatic arthritis (PsA).

This article summarized the latest R&D progress of Nemolizumab, the Mechanism of Action for Nemolizumab, and the drug target R&D trends for Nemolizumab.

Challenging the pathogenicity of bacteria through Bacteriophage therapy could lead the way to improved antibiotic strategies.

This article summarized the latest R&D progress of Mycophenolate Sodium, the mechanism of action for Mycophenolate Sodium, and the drug target R&D trends for Mycophenolate Sodium.